Impact of target-mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.

Zhenlei WangZhijun ZengLijun YeXiaohong ZhuYuwen PeiYongsheng WangLi Zheng

Published in: British journal of clinical pharmacology (2021)

TMDD was the primary reason leading to nonlinear PK profile of hetrombopag. Our PK/PD modelling and simulation results support 10 mg once-daily as the recommended therapeutic dose for chronic ITP patients in subsequent confirmatory clinical study of hetrombopag.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
physical activity
prognostic factors
clinical trial
emergency department